Literature DB >> 23680920

Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.

Krupa J Patel1, Olivier Trédan, Ian F Tannock.   

Abstract

PURPOSE: Pharmacokinetic analyses estimate the mean concentration of drug within a given tissue as a function of time, but do not give information about the spatial distribution of drugs within that tissue. Here, we compare the time-dependent spatial distribution of three anticancer drugs within tumors, heart, kidney, liver and brain.
METHODS: Mice bearing various xenografts were treated with doxorubicin, mitoxantrone or topotecan. At various times after injection, tumors and samples of heart, kidney, liver and brain were excised.
RESULTS: Within solid tumors, the distribution of doxorubicin, mitoxantrone and topotecan was limited to perivascular regions at 10 min after administration and the distance from blood vessels at which drug intensity fell to half was ~25-75 μm. Although drug distribution improved after 3 and 24 h, there remained a significant decrease in drug fluorescence with increasing distance from tumor blood vessels. Drug distribution was relatively uniform in the heart, kidney and liver with substantially greater perivascular drug uptake than in tumors. There was significantly higher total drug fluorescence in the liver than in tumors after 10 min, 3 and 24 h. Little to no drug fluorescence was observed in the brain.
CONCLUSIONS: There are marked differences in the spatial distributions of three anticancer drugs within tumor tissue and normal tissues over time, with greater exposure to most normal tissues and limited drug distribution to many cells in tumors. Studies of the spatial distribution of drugs are required to complement pharmacokinetic data in order to better understand and predict drug effects and toxicities.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23680920     DOI: 10.1007/s00280-013-2176-z

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  21 in total

1.  Nanoparticle-based brachytherapy spacers for delivery of localized combined chemoradiation therapy.

Authors:  Rajiv Kumar; Jodi Belz; Stacey Markovic; Tej Jadhav; William Fowle; Mark Niedre; Robert Cormack; Mike G Makrigiorgos; Srinivas Sridhar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-02-01       Impact factor: 7.038

Review 2.  p53 and Cell Fate: Sensitizing Head and Neck Cancer Stem Cells to Chemotherapy.

Authors:  Christie Rodriguez-Ramirez; Jacques E Nör
Journal:  Crit Rev Oncog       Date:  2018

3.  Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts.

Authors:  Carles Monterrubio; Sonia Paco; Monica Vila-Ubach; Eva Rodríguez; Romina Glisoni; Cinzia Lavarino; Paula Schaiquevich; Alejandro Sosnik; Jaume Mora; Angel M Carcaboso
Journal:  Pharm Res       Date:  2015-03-14       Impact factor: 4.200

Review 4.  Cytotoxic mechanisms of doxorubicin at clinically relevant concentrations in breast cancer cells.

Authors:  Rachel E Nicoletto; Clyde M Ofner
Journal:  Cancer Chemother Pharmacol       Date:  2022-02-12       Impact factor: 3.333

5.  Effect of Theobroma cacao L. on the Efficacy and Toxicity of Doxorubicin in Mice Bearing Ehrlich Ascites Carcinoma.

Authors:  Priyanka P Patil; Pukar Khanal; Vishal S Patil; Rajitha Charla; Darasaguppe R Harish; Basanagouda M Patil; Subarna Roy
Journal:  Antioxidants (Basel)       Date:  2022-05-31

6.  A phase I trial of pantoprazole in combination with doxorubicin in patients with advanced solid tumors: evaluation of pharmacokinetics of both drugs and tissue penetration of doxorubicin.

Authors:  Irene Brana; Alberto Ocana; Eric X Chen; Albiruni R A Razak; Christine Haines; Carol Lee; Sarah Douglas; Lisa Wang; Lillian L Siu; Ian F Tannock; Philippe L Bedard
Journal:  Invest New Drugs       Date:  2014-09-12       Impact factor: 3.850

7.  A technology platform to assess multiple cancer agents simultaneously within a patient's tumor.

Authors:  S Bahram Bahrami; Beryl A Hatton; Richard A Klinghoffer; Jason P Frazier; Alicia Moreno-Gonzalez; Andrew D Strand; William S Kerwin; Joseph R Casalini; Derek J Thirstrup; Sheng You; Shelli M Morris; Korashon L Watts; Mandana Veiseh; Marc O Grenley; Ilona Tretyak; Joyoti Dey; Michael Carleton; Emily Beirne; Kyle D Pedro; Sally H Ditzler; Emily J Girard; Thomas L Deckwerth; Jessica A Bertout; Karri A Meleo; Ellen H Filvaroff; Rajesh Chopra; Oliver W Press; James M Olson
Journal:  Sci Transl Med       Date:  2015-04-22       Impact factor: 17.956

Review 8.  Mesenchymal stem cell therapy for doxorubicin cardiomyopathy: hopes and fears.

Authors:  Fernando Ezquer; Jaime Gutiérrez; Marcelo Ezquer; Christian Caglevic; Helio C Salgado; Sebastián D Calligaris
Journal:  Stem Cell Res Ther       Date:  2015-06-24       Impact factor: 6.832

9.  Relationship between therapeutic efficacy of doxorubicin-transferrin conjugate and expression of P-glycoprotein in chronic erythromyeloblastoid leukemia cells sensitive and resistant to doxorubicin.

Authors:  Marzena Szwed; Katarzyna D Kania; Zofia Jozwiak
Journal:  Cell Oncol (Dordr)       Date:  2014-11-20       Impact factor: 6.730

10.  Influence of the proton pump inhibitor lansoprazole on distribution and activity of doxorubicin in solid tumors.

Authors:  Man Yu; Carol Lee; Marina Wang; Ian F Tannock
Journal:  Cancer Sci       Date:  2015-09-25       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.